

Special Issue

Growth Factors of the Peripheral Nervous System and Neurotrophin Family

Message from the Guest Editor

The growth factors included in the family of neurotrophins (NGF, BDNF, NT3, NT4/5 and NT6—the latter only present in fish) constitute the paradigm of bioactive molecules with neurotrophic and neurotropic activities, especially in the peripheral nervous system. Almost 75 years have passed since the first member of the family (NGF) was discovered, and more than 30 years since the discovery of the high-affinity receptors that signal its biological functions. It was originally established that NGF was related to nociceptive primary sensory neurons and peripheral sympathetic neurons, BDNF to touch mechanoreceptive primary sensory neurons, NT3 to proprioceptive primary sensory neurons and to the enteric nervous system. But it was found that the relationships of the growth factors of this family with the peripheral nervous system are much more complex. Likewise, it is of the utmost interest to compile the therapeutic potential of this family of growth factors in the treatment of peripheral neuropathies and pathologies of the peripheral nervous system due to mutations in neurotrophins or their receptors, such as insensitivity to pain with anhidrosis.

Guest Editor

Prof. Dr. José A. Vega

1. Departamento de Morfología y Biología Celular, Grupo SINPOS, Universidad de Oviedo, Avda, Julián Clavería 6, 33006 Oviedo, Spain
2. Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Santiago, Chile

Deadline for manuscript submissions

closed (30 April 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/188839

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).